The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://bookmarkproduct.com/story20810080/retatrutide-vs-tirzepatide-a-comparative-analysis